FIELD: medicine.
SUBSTANCE: invention relates to medicine and deals with method of inducing apoptotic death of skin melanoma cells, which includes application of ligand TsPO PK11 195 and inhibitor of MEK kinase UO126, characterised by the fact that by means of method of RFLP analysis presence of mutation in gene BRAF V600E is determined in patient with skin melanoma by method of RFLP analysis and in case of its presence in order to induce apoptosis inhibitor of MEK kinase UO126 is additionally used together with PK11 195 in concentration: PK11 195 10 nmol/L, UO126 10 umol/L.
EFFECT: invention ensures effective impact on processes of apoptosis and cell proliferation of skin melanoma, which influences therapy in general.
1 cl, 1 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION | 2010 |
|
RU2553379C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS | 2016 |
|
RU2760835C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| BRAF MUTATIONS ENSUING RESISTANCE TO BRAF INHIBITORS | 2011 |
|
RU2571930C2 |
| METHOD FOR COMPLEX PREOPERATIVE DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT NODULES OF THE THYROID GLAND | 2022 |
|
RU2805941C1 |
| METHOD OF PRODUCTION OF SUBDERMAL XENOGRAFTS OF CELL LINE OF PEOPLE SKIN MELANOMA mel Cher WITH MUTATION V600E BRAF FOR PRECLINICAL STUDY OF ANTINEOPLASTIC TARGETED AGENTS | 2014 |
|
RU2572569C1 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| HUMAN SKIN MELANOMA CELL LINE mel-Alx-LP | 2022 |
|
RU2796357C1 |
